E. Banaga

Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma

A. Casadevall, J. Schachter, G. Denardo, 2013, Journal of skin cancer.

Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.

S. Shen, R. Meredith, E. Banaga, 2014, Cancer biotherapy & radiopharmaceuticals.

Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients withMetastatic Melanoma

A. Casadevall, J. Schachter, G. Denardo, 2013 .

Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients

S. Shen, R. Meredith, E. Banaga, 2013 .

Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

M. Brechbiel, A. Molinolo, D. Milenic, 2015, Pharmaceuticals.

First in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab

S. Shen, R. Alvarez, R. Meredith, 2013 .

Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab

Julien Torgue, Sui Shen, Jinda Fan, 2014, The Journal of Nuclear Medicine.

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab

M. Dobelbower, A. Lowy, R. Alvarez, 2016, American journal of clinical oncology.